Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/02/21 | 1,192 | 1,244 | 1,155 | 1,174 | ±0 | ±0% | 746,000 |
| 2023/02/20 | 1,176 | 1,240 | 1,155 | 1,174 | -29 | -2.4% | 794,800 |
| 2023/02/17 | 1,241 | 1,277 | 1,182 | 1,203 | -43 | -3.5% | 1,687,500 |
| 2023/02/16 | 1,145 | 1,324 | 1,119 | 1,246 | +107 | +9.4% | 3,098,300 |
| 2023/02/15 | 1,043 | 1,148 | 1,038 | 1,139 | +141 | +14.1% | 1,396,300 |
| 2023/02/14 | 1,047 | 1,047 | 990 | 998 | -79 | -7.3% | 657,900 |
| 2023/02/13 | 1,022 | 1,082 | 1,010 | 1,077 | +47 | +4.6% | 618,200 |
| 2023/02/10 | 1,021 | 1,040 | 1,002 | 1,030 | -4 | -0.4% | 295,500 |
| 2023/02/09 | 1,038 | 1,060 | 1,031 | 1,034 | -20 | -1.9% | 252,400 |
| 2023/02/08 | 1,063 | 1,070 | 1,042 | 1,054 | -18 | -1.7% | 248,600 |
| 2023/02/07 | 1,069 | 1,090 | 1,052 | 1,072 | ±0 | ±0% | 283,200 |
| 2023/02/06 | 1,069 | 1,102 | 1,052 | 1,072 | -7 | -0.6% | 303,800 |
| 2023/02/03 | 1,148 | 1,162 | 1,074 | 1,079 | -91 | -7.8% | 721,900 |
| 2023/02/02 | 1,142 | 1,199 | 1,134 | 1,170 | +36 | +3.2% | 355,300 |
| 2023/02/01 | 1,134 | 1,165 | 1,106 | 1,134 | +5 | +0.4% | 227,000 |
| 2023/01/31 | 1,111 | 1,135 | 1,095 | 1,129 | -3 | -0.3% | 231,600 |
| 2023/01/30 | 1,106 | 1,153 | 1,086 | 1,132 | +8 | +0.7% | 613,700 |
| 2023/01/27 | 1,180 | 1,184 | 1,120 | 1,124 | -70 | -5.9% | 556,600 |
| 2023/01/26 | 1,258 | 1,267 | 1,130 | 1,194 | -64 | -5.1% | 1,168,300 |
| 2023/01/25 | 1,214 | 1,295 | 1,208 | 1,258 | +38 | +3.1% | 968,100 |
| 2023/01/24 | 1,242 | 1,265 | 1,197 | 1,220 | +7 | +0.6% | 899,800 |
| 2023/01/23 | 1,214 | 1,233 | 1,185 | 1,213 | -1 | -0.1% | 653,700 |
| 2023/01/20 | 1,130 | 1,228 | 1,130 | 1,214 | +66 | +5.7% | 537,600 |
| 2023/01/19 | 1,106 | 1,170 | 1,091 | 1,148 | +28 | +2.5% | 358,300 |
| 2023/01/18 | 1,089 | 1,131 | 1,068 | 1,120 | +1 | +0.1% | 499,800 |
| 2023/01/17 | 1,151 | 1,167 | 1,103 | 1,119 | -53 | -4.5% | 759,900 |
| 2023/01/16 | 1,206 | 1,224 | 1,138 | 1,172 | -78 | -6.2% | 823,700 |
| 2023/01/13 | 1,234 | 1,265 | 1,201 | 1,250 | +31 | +2.5% | 485,700 |
| 2023/01/12 | 1,317 | 1,322 | 1,212 | 1,219 | -96 | -7.3% | 724,400 |
| 2023/01/11 | 1,349 | 1,379 | 1,305 | 1,315 | -34 | -2.5% | 421,500 |
| 2023/01/10 | 1,325 | 1,350 | 1,216 | 1,349 | -6 | -0.4% | 962,100 |
| 2023/01/06 | 1,221 | 1,371 | 1,213 | 1,355 | +126 | +10.3% | 861,800 |
| 2023/01/05 | 1,210 | 1,240 | 1,175 | 1,229 | +18 | +1.5% | 341,900 |
| 2023/01/04 | 1,275 | 1,299 | 1,195 | 1,211 | -61 | -4.8% | 734,800 |
| 2022/12/30 | 1,218 | 1,281 | 1,185 | 1,272 | +84 | +7.1% | 876,800 |
| 2022/12/29 | 1,185 | 1,203 | 1,142 | 1,188 | +3 | +0.3% | 335,400 |
| 2022/12/28 | 1,147 | 1,220 | 1,118 | 1,185 | +23 | +2% | 653,000 |
| 2022/12/27 | 1,049 | 1,177 | 1,042 | 1,162 | +137 | +13.4% | 528,500 |
| 2022/12/26 | 998 | 1,030 | 930 | 1,025 | +40 | +4.1% | 249,400 |
| 2022/12/23 | 990 | 996 | 962 | 985 | -15 | -1.5% | 79,600 |
| 2022/12/22 | 976 | 1,020 | 965 | 1,000 | +17 | +1.7% | 143,800 |
| 2022/12/21 | 977 | 1,009 | 960 | 983 | +7 | +0.7% | 153,600 |
| 2022/12/20 | 983 | 1,007 | 945 | 976 | -24 | -2.4% | 168,400 |
| 2022/12/19 | 1,025 | 1,052 | 989 | 1,000 | -35 | -3.4% | 190,300 |
| 2022/12/16 | 1,028 | 1,087 | 1,014 | 1,035 | +7 | +0.7% | 357,200 |
| 2022/12/15 | 984 | 1,040 | 984 | 1,028 | +44 | +4.5% | 163,800 |
| 2022/12/14 | 988 | 1,015 | 980 | 984 | -5 | -0.5% | 201,000 |
| 2022/12/13 | 934 | 999 | 931 | 989 | +53 | +5.7% | 195,400 |
| 2022/12/12 | 941 | 980 | 927 | 936 | -4 | -0.4% | 202,900 |
| 2022/12/09 | 841 | 940 | 836 | 940 | +90 | +10.6% | 359,300 |
551～
600
件表示中 / 1611件
類似銘柄と比較する
現在ご覧いただいている「ＤＥＬＴＡ－Ｐ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＤＥＬＴＡ－Ｐ | 57,200円 | - | - | 0.00% | - | 20.24倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
| モダリス | 7,600円 | - | - | 0.00% | - | 1.62倍 |
|
遺伝子治療薬の創薬ベンチャー、ＤＮＡ切断しないエピゲノム編集に強み。研究開発中心は米国 |
| カイノス | 123,600円 | +3.7% | +2.7% | 2.59% | 8.68倍 | 0.77倍 |
|
臨床検査薬の中堅メーカー。生化学、免疫血清学的検査用試薬に重点。共同開発の促進に注力 |
| カルナバイオ | 28,100円 | +13.5% | - | 0.00% | - | 2.17倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ＤＷＴＩ | 11,300円 | -15.1% | - | 0.00% | - | 7.06倍 |
|
三重大学発創薬ベンチャー。プロテインキナーゼ阻害剤開発技術はじめ眼病治療薬開発に集中 |
市場注目の銘柄
チャート関連のコラム
